Syros Pharmaceuticals Inc (NAS:SYRS)
$ 1.5675 -0.035 (-2.18%) Market Cap: 42.02 Mil Enterprise Value: 24.59 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 38/100

Q4 2018 Syros Pharmaceuticals Inc Earnings Call Transcript

Mar 07, 2019 / 01:30PM GMT
Release Date Price: $69 (-2.40%)
Operator

Good day, ladies and gentlemen, and welcome to the Quarter 4 2018 Syros Pharmaceuticals, Inc. Earnings Conference Call. (Operator Instructions) I would now like to introduce your host for today's conference, Naomi Aoki, Vice President of Corporate Communications and Investor Relations for Syros. Please go ahead.

Naomi Aoki
Syros Pharmaceuticals, Inc. - VP of Corporate Communications & IR

Thank you. This morning, we issued a press release with our fourth quarter and full year 2018 financial results, along with anticipated future milestones and recent accomplishments. This release is available on the Investors & Media section of Syros' website at www.syros.com.

We will begin the call with prepared remarks by Dr. Nancy Simonian, our Chief Executive Officer; Dr. David Roth, our Chief Medical Officer; and Joe Ferra, our Chief Financial Officer. Then we will open the call for questions. Dr. Eric Olson, our Chief Scientific Officer; and Dr. Jeremy Springhorn, our Chief Business Officer,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot